| pubmed-article:2840229 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2840229 | lifeskim:mentions | umls-concept:C0010825 | lld:lifeskim |
| pubmed-article:2840229 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:2840229 | lifeskim:mentions | umls-concept:C0022671 | lld:lifeskim |
| pubmed-article:2840229 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:2840229 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:2840229 | lifeskim:mentions | umls-concept:C0001367 | lld:lifeskim |
| pubmed-article:2840229 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:2840229 | lifeskim:mentions | umls-concept:C0301625 | lld:lifeskim |
| pubmed-article:2840229 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2840229 | pubmed:dateCreated | 1988-9-8 | lld:pubmed |
| pubmed-article:2840229 | pubmed:abstractText | The pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease were evaluated in 12 patients undergoing renal transplantation. A 12-week course beginning 24 hours before transplantation was administered in doses of 800 to 3200 mg/day based on renal function. Acyclovir plasma concentrations were measured by RIA on posttransplant days 1 or 2 and 5, 6, or 7. Mean peak and trough concentrations on days 5, 6 or 7 were 25 and 18 mumol/L, respectively. The pharmacokinetic model predicted acyclovir concentrations with a precision of 4.1 mumol/L and bias of -1.19 mumol/L. Estimates of individual pharmacokinetic parameters were consistent with literature and a priori values. Two of six adverse events were attributable to acyclovir; both resolved with dose modification. The dosage adjustment scheme and pharmacokinetic model performed well, allowing us to safely administer high-dose oral acyclovir immediately after renal transplantation. We are proceeding with a placebo-controlled study to assess efficacy for suppression of posttransplant cytomegalovirus disease. | lld:pubmed |
| pubmed-article:2840229 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2840229 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2840229 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2840229 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2840229 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2840229 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2840229 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:2840229 | pubmed:issn | 0009-9236 | lld:pubmed |
| pubmed-article:2840229 | pubmed:author | pubmed-author:BalfourH... | lld:pubmed |
| pubmed-article:2840229 | pubmed:author | pubmed-author:FletcherC VCV | lld:pubmed |
| pubmed-article:2840229 | pubmed:author | pubmed-author:ChinnockB JBJ | lld:pubmed |
| pubmed-article:2840229 | pubmed:author | pubmed-author:ChaceBB | lld:pubmed |
| pubmed-article:2840229 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2840229 | pubmed:volume | 44 | lld:pubmed |
| pubmed-article:2840229 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2840229 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2840229 | pubmed:pagination | 158-63 | lld:pubmed |
| pubmed-article:2840229 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2840229 | pubmed:meshHeading | pubmed-meshheading:2840229-... | lld:pubmed |
| pubmed-article:2840229 | pubmed:meshHeading | pubmed-meshheading:2840229-... | lld:pubmed |
| pubmed-article:2840229 | pubmed:meshHeading | pubmed-meshheading:2840229-... | lld:pubmed |
| pubmed-article:2840229 | pubmed:meshHeading | pubmed-meshheading:2840229-... | lld:pubmed |
| pubmed-article:2840229 | pubmed:meshHeading | pubmed-meshheading:2840229-... | lld:pubmed |
| pubmed-article:2840229 | pubmed:meshHeading | pubmed-meshheading:2840229-... | lld:pubmed |
| pubmed-article:2840229 | pubmed:meshHeading | pubmed-meshheading:2840229-... | lld:pubmed |
| pubmed-article:2840229 | pubmed:meshHeading | pubmed-meshheading:2840229-... | lld:pubmed |
| pubmed-article:2840229 | pubmed:meshHeading | pubmed-meshheading:2840229-... | lld:pubmed |
| pubmed-article:2840229 | pubmed:meshHeading | pubmed-meshheading:2840229-... | lld:pubmed |
| pubmed-article:2840229 | pubmed:meshHeading | pubmed-meshheading:2840229-... | lld:pubmed |
| pubmed-article:2840229 | pubmed:meshHeading | pubmed-meshheading:2840229-... | lld:pubmed |
| pubmed-article:2840229 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2840229 | pubmed:articleTitle | Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation. | lld:pubmed |
| pubmed-article:2840229 | pubmed:affiliation | Department of Pharmaceutical Services, University of Minnesota, Health Sciences Center, Minneapolis. | lld:pubmed |
| pubmed-article:2840229 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2840229 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2840229 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2840229 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2840229 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2840229 | lld:pubmed |
